Brokerages Set Cellebrite DI Ltd. (NASDAQ:CLBT) Price Target at $12.42

Cellebrite DI Ltd. (NASDAQ:CLBT) has received a consensus recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $12.42.

CLBT has been the topic of several research reports. William Blair upgraded shares of Cellebrite DI from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 13th. Needham & Company LLC upped their target price on shares of Cellebrite DI from $13.00 to $13.50 and gave the stock a “buy” rating in a report on Thursday, March 28th. Lake Street Capital started coverage on shares of Cellebrite DI in a report on Friday, April 19th. They issued a “buy” rating and a $13.00 target price on the stock. Craig Hallum upped their target price on shares of Cellebrite DI from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Finally, Bank of America upped their target price on shares of Cellebrite DI from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, April 1st.

Institutional Investors Weigh In On Cellebrite DI

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP increased its stake in Cellebrite DI by 574.0% in the 1st quarter. GSA Capital Partners LLP now owns 286,930 shares of the company’s stock valued at $3,179,000 after buying an additional 244,357 shares during the last quarter. Capstone Investment Advisors LLC bought a new position in shares of Cellebrite DI during the 1st quarter valued at approximately $870,000. Janney Montgomery Scott LLC grew its position in shares of Cellebrite DI by 240.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 45,300 shares of the company’s stock valued at $502,000 after acquiring an additional 31,981 shares during the period. Meritage Portfolio Management bought a new position in shares of Cellebrite DI during the 1st quarter valued at approximately $272,000. Finally, Counterpoint Mutual Funds LLC bought a new position in shares of Cellebrite DI during the 1st quarter valued at approximately $657,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Trading Down 1.2 %

Shares of NASDAQ CLBT opened at $10.72 on Thursday. The firm’s 50-day moving average price is $11.23 and its 200-day moving average price is $9.44. Cellebrite DI has a 1-year low of $5.22 and a 1-year high of $12.50. The firm has a market capitalization of $2.20 billion, a P/E ratio of -24.93, a P/E/G ratio of 1.91 and a beta of 1.51.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Thursday, February 15th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.02. Cellebrite DI had a negative net margin of 24.94% and a positive return on equity of 173.14%. The firm had revenue of $93.01 million for the quarter, compared to analyst estimates of $85.43 million. Equities research analysts forecast that Cellebrite DI will post 0.32 EPS for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.